Study of the Rate of Progression of Cerebral Ischemia in Afro-Caribbeans

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

135 participants

Study Classification

OBSERVATIONAL

Study Start Date

2026-01-31

Study Completion Date

2028-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To compare the progression of cerebral ischemia from HF in Afro-Caribbean patients admitted to the CHUG to that of patients from Nantes included in the national ETIS registry.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Novel Risk Factors and Localization of Peripheral Arterial Disease

NCT07233356

Atherosclerotic Peripheral Arterial Disease Hemoglobin A1c Protein, Human Guadeloupe

COMPLETED

A Longitudinal Cohort Study to Evaluate Cardiovascular Risk Factors and Disease in Haiti

NCT03892265

Hypertension Diabetes Obesity +11 more

ACTIVE_NOT_RECRUITING

STUDY OF THE DOUBLE POLYMORPHISM (THR 555ILE) AND (GLU568PRO) OF THE CORIN GENE AS A RISK FACTOR FOR ARTERIAL HYPERTENSION IN A POPULATION OF AFRICAN DESCENT IN GUADELOUPE

NCT07330804

High Blood Pressure

RECRUITING NA

Identifying Genes That May Increase the Risk for Heart Disease in African Americans

NCT00344136

Heart Diseases

COMPLETED

Clinical Course of Coronary Artery Disease Among Blacks

NCT00005191

Cardiovascular Diseases Coronary Disease Myocardial Infarction +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

mpare the progression of cerebral ischemia of IC in Afro-Caribbean patients admitted to the CHUG with that of patients from Nantes included in the national register ETIS.

Secondary outcomes: Stroke is a sudden interruption of blood flow in the brain. Among the types of stroke, cerebral infarction is the most common (80% of cases). Cerebral infarction (CI) is a sudden disruption of brain circulation due to the occlusion of an artery by a clot. Large vessel occlusions (OLV) of the brain represent 30-40% of occlusions and are frequently associated with poor prognosis. Mechanical thrombectomy (MT) involves the extraction of the intra-arterial thrombus. Often performed in conjunction with intravenous thrombolysis (TIV), it has become the preferred treatment for OLV. However, not all patients with OLV are eligible for TM. It is recognized that for the same occlusion site, the rate of progression of HF varies from individual to individual. There are two categories of patients: the "fast progressor" and the "slow progressor". Patients referred to as "fast progressor" have a higher volume CI than "slow progressors" for the same time delay between onset of symptoms and imaging. The "fast progressor" profile is usually associated with an unfavourable functional prognosis. In the study by Rocha et al (ref. n°8), assessing the prevalence and distribution of ischemic volume progression rate in patients with OLV; 58% of patients had ischemic volume 30 mL and 72% had ischemic volume 70 mL within 24 hours after the onset of stroke. These patients were characterized as "slow progressors".

In 2022, a retrospective preliminary study was carried out at the Guadeloupe University Hospital and allowed for a comparison of patients treated within the institution with those of patients from the ETIS Register recording thrombectomies performed nationally. The comparison between the two populations shows that patients who have suffered a stroke in Guadeloupe are of type "fast progressor".

We hypothesize that the Afro-Caribbean patients admitted to CHUG for IC would be mostly "fast progressors".

The rate of progression will be determined using brain imaging from the measurement of ischemia volume. This faster progression could be explained by several factors including (1) differences in blood supply between the two populations; (2) environmental and climatic conditions and (3) epigenetic and genetic factors

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ischemic Stroke Cerebral Ischemia Endovascular Treatments

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients residing in Guadeloupe

No Interventions

Intervention Type OTHER

No interventions

Patients residing in Nantes

No Interventions

Intervention Type OTHER

No interventions

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No Interventions

No interventions

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 18 and over, admitted for IC due to LVO verified by medical imaging and hospitalized in neurology.
* Patients residing in Guadeloupe
* Afro-Caribbean patients: of African ancestry.
* Emergency inclusion, with exemption from obtaining consent due to the immediate life-threatening emergency situation of the patient (Article L1122-1-3 of the French Public Health Code); as soon as possible, consent to continue will be sought from the patient or, if applicable, from a relative or a trusted person.
* Patients affiliated to a social security scheme or equivalent

Exclusion Criteria

* Patients under 18 years old
* Non-resident patients in Guadeloupe
* Protected persons (articles L1121-5, L1121-6 and L121-8 of the Public Health Code): pregnant or breastfeeding women, persons deprived of their liberty, under guardianship or curatorship)
* Withdrawal of consent during the study
* Patients not affiliated to a social security or equivalent scheme

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No